Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 201–300 of 1,035
Hypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 394
Sorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394
“In preclinical models, anti-VEGF agents rapidly but transiently ‘‘normalize’’ the structure and function of glioblastoma vessels— they decrease vessel diameter and permeability, increase tumor oxygenation, and induce a thinning of the abnormally thick basement membrane (9, 10).”
BackgroundSelf-citationSilencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
“VEGF inhibitors induce vessel normalization during a particular time window (Batchelor et al., 2007; Jain, 2005); since this process has been related to increased drug delivery, it has been questioned whether pretreatment of cancer patients with VEGF inhibitors would improve chemotherapy.”
BackgroundLee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Karamysheva, A. F. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908070031 · Cited by 386
Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, D. J., & Kerbel, R. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4238 · Cited by 385
“reduced hypoxia within tumors (18), slowing down tumor cell repopulation between successive cycles of chemotherapy (19) and facilitating the targeting of dividing endothelial cells in the tumor”
BackgroundOverchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
“Collectively, these changes decrease interstitial f luid pressure, increase tumor oxygenation, and enhance drug tissue penetration [75,180].”
BackgroundNonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
“Tumor vasculatures are chaotic, poorly structured, unevenly branched, and heterogeneously distributed in the tumor, making unordered spatial distribution of nanomedicines or vectors [107, 108].”
BackgroundStimuli‐Responsive Materials for Controlled Release of Theranostic Agents
Wang, Y., Shim, M. S., Levinson, N. S., Sung, H., & Xia, Y. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201400279 · Cited by 378
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
“Targeting CAFs for cancer treatment is believed to have two benefits: 1) the ongoing function of CAFs is critical to the growth of nearby neoplastic cells, and 2) stromal cells are more genetically stable than carcinoma cells, which can accumulate adaptive mutations during the course of therapy to acquire drug resista…”
BackgroundDong, D., Ni, M., Li, J., Xiong, S., Ye, W., Virrey, J. J., Mao, C., Ye, R., Wang, M., Pen, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2950 · Cited by 375
“Tumor angiogenesis plays a critical role in tumor growth and is a key target for anticancer therapy (39, 40).”
BackgroundTherapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Photodynamic therapy for hypoxic tumors: Advances and perspectives
Huang, L., Zhao, S., Wu, J., Yu, L., Singh, N., Yang, K., Lan, M., Wang, P., & Kim, J. S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213888 · Cited by 366
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment
Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 370
“Following antiangiogenesis treatment, the tumor vasculature may undergo morphologic normalization, whereby immature blood vessels are pruned, blood vessel tortuosity and dilation decrease, and a closer association between pericytes and endothelial cells is induced (71).”
BackgroundHypoxia, inflammation, and the tumor microenvironment in metastatic disease
Finger, E. C., & Giaccia, A. J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9224-5 · Cited by 370
Cairns, R., Papandreou, I., & Denko, N. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0002 · Cited by 370
“This mechanism is thought to be through vascular normalization that results in reduced protein leakage into the interstitium and better laminar flow through the vessels (56).”
BackgroundInfluentialMechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
“Although anti-angiogenesis monotherapies have yielded only modest survival benefit in the clinic, an important observation that some of them can normalize the vasculature was made [103, 243].”
BackgroundThe role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
The metastasis-promoting roles of tumor-associated immune cells
Smith, H. A., & Kang, Y. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1021-5 · Cited by 367
“The impact of this aberrant vasculature essentially inhibits the efficient extravasation of cytotoxic lymphocytes with effector functionality into the tumor microenvironment [188].”
BackgroundOdyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
“However, vascular normalization monotherapy met several challenges, such as the detailed functional mechanisms, the window of normalization monitoring, and time-consuming initiation with shortlived maintenance [278].”
BackgroundVascular Permeability and Drug Delivery in Cancers
Azzi, S., Hebda, J. K., & Gavard, J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00211 · Cited by 356
“Indeed for each anti-cancer therapy, a “normalization window,” has to be determined to define period and doses necessary for tumor vessel normalization (148).”
BackgroundMacrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Corliss, B. A., Azimi, M. S., Munson, J. M., Peirce, S. M., & Murfee, W. L. (2016) · Microcirculation · doi:10.1111/micc.12259 · Cited by 356
“There are numerous outstanding reviews chronicling the structure [78], function [125], mechanistic regulation [294], and inhibition [80,126] of tumor-associated blood vessels.”
BackgroundNanodrug applications in photodynamic therapy
Paszko, E., Ehrhardt, C., Senge, M. O., Kelleher, D. P., & Reynolds, J. V. (2011) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2010.12.001 · Cited by 356
“For example, a targeted verteporfin conjugate was prepared by modification of polyvinyl alcohol polymer, followed by linkage to the peptide ATWLPPR, which binds to the vascular endothelial growth factor receptor (VEGFR2) and showed improved PDT effects [145].”
InfluentialA systems view of the vascular endothelium in health and disease
Augustin, H. G., & Koh, G. Y. (2024) · Cell · doi:10.1016/j.cell.2024.07.012 · Cited by 343
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Self-citationPhysiologically Based Pharmacokinetic Modeling of Nanoparticles
Li, M., Al-Jamal, K. T., Kostarelos, K., & Reineke, J. (2010) · ACS Nano · doi:10.1021/nn1018818 · Cited by 351
“Tumor blood vessels are leaky, tortuous, and dilated, and their endothelial cells lining have aberrant morphology with the basement membrane often being abnormal.(64) Their high vascular density, vascular leakiness, and impaired lymphatic recovery lead to an enhanced permeability and retention (EPR) effect for nanopar…”
BackgroundXie, C., Wan, X., Quan, H., Zheng, M., Fu, L., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 348
“Neutralizing VEGF/ VEGFR2 interactions with monoclonal antibodies and blocking VEGFR kinase activity with small-molecule inhibitors are major approaches for targeting VEGF/VEGFR signaling in the treatment of solid tumors.(42,43) Several oral, non-specific VEGFR2 TKI have been approved for cancer therapy in the past 10…”
MethodAnti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Humphries, B., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3052 · Cited by 346
“In addition to these mechanisms, new blood vessels that have been formed by the primary tumor are leaky and therefore can also facilitate intravasation [70, 71].”
BackgroundPericytes limit tumor cell metastasis
Xian, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25705 · Cited by 345
Batchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340
Self-citationKudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02575-3 · Cited by 342
Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., Imle, A., Freire Valls, A., Radhakrishnan, P., Liang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.005 · Cited by 339
Pandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., Beckman, J. A., Harrison, D. G., & Moslehi, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 338
“Preliminary data suggest vascular pruning of structurally and functionally abnormal vessels supplying solid tumors by anti-VEGF therapies.(30) There is clinical evidence of rarefaction of nontumor, systemic microvessels in patients treated with VSP inhibitors.”
BackgroundDrug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
“, 2007) and thereby contribute to improved delivery of subsequent chemotherapy, enhancing efficacy (Jain, 2005).”
BackgroundMechanisms and impact of altered tumour mechanics
Mohammadi, H., & Sahai, E. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0131-2 · Cited by 336
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
“microenvironment is not only hypoxic and acidic but also is surrounded by high interstitial pressure, which acts as a pathologic barrier to drug delivery into tumors (Gatenby and Gillies, 2004; Hockel and Vaupel, 2001; Jain, 2005).”
BackgroundInfluentialLiu, J., Liao, S., Diop-Frimpong, B., Chen, W., Goel, S., Naxerova, K., Ancukiewicz, M., Boucher, Y., Jain, R. K., & Xu, L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117610109 · Cited by 330
“First, TGF-β blockade normalizes tumor vasculature—manifested by a reduction in vessel density, improved vessel maturity, and increased perfusion of vessels—and improves chemotherapy delivery into tumors (26).”
BackgroundSelf-citationStrategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis
Kryczek, I., Wei, S., Keller, E., Liu, R., & Zou, W. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00406.2006 · Cited by 329
Biology of hypoxia-inducible factor-2α in development and disease
Patel, S. A., & Simon, M. C. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.17 · Cited by 327
Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement
Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.008 · Cited by 327
Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer
Provenzano, P. P., & Hingorani, S. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.569 · Cited by 323
“…that inhibit or normalise angiogenesis are not effective in treating PDA in either humans (Kindler et al, 2010, 2011) or mice (Olson et al, 2011), despite their proven utility in typically hypervascular pancreatic neuroendocrine tumours (Raymond et al, 2011) and other malignancies (Jain, 2005).”
BackgroundIntegrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
“[Jain, 2005].”
BackgroundGong, Z., & Dai, Z. (2021) · Advanced Science · doi:10.1002/advs.202002178 · Cited by 320
Pathogenesis and Prevention of Intraventricular Hemorrhage
Ballabh, P. (2014) · Clinics in Perinatology · doi:10.1016/j.clp.2013.09.007 · Cited by 319
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
“As such, an attractive possibility is remodeling aberrant tumor blood vessels, which can restore the structure and function of vasculature and then improve the drug penetration, as well as achieve better outcomes, currently known as “vascular normalization” [351, 353].”
BackgroundPeterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Self-citationVHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
“Tumour vessel normalization is gaining attention as a strategy to combat cancer because of the resultant improved drug delivery [150] and the smaller risk for resistance to this kind of therapy, since endothelial cells are genetically stable cells.”
BackgroundKudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Spaide, R. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.012 · Cited by 313
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 311
Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309
“Furthermore, intravital microscopy measurements demonstrated that cediranib significantly decreased tumor vessel permeability and diameter, as well as vascular hemoconcentration (elevated hematocrit, Figs 3B through 3E and 4), all hallmarks of tumor vascular normalization.(19) Given the decrease in vessel diameter see…”
BackgroundSelf-citationKudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309
“In addition, as is very well known, antiangiogenic agents play a very important role in the normalization of tumor vasculature [44] and in the enhancement of the effective, homogeneous delivery of anticancer agents (including lipiodol and gelatin sponge) into tumor tissues [45], resulting in improved responses to TACE…”
BackgroundKoh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0463 · Cited by 309
“flow in the structurally and functionally abnormal tumor blood vessels (4).”
BackgroundModulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors
Liu, Y., Jiang, Y., Zhang, M., Tang, Z., He, M., & Bu, W. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00214 · Cited by 307
Migrating into the tumor: a roadmap for T cells
van der Woude, L. L., Gorris, M. A. J., Halilovic, A., Figdor, C. G., & de Vries, I. J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.006 · Cited by 307
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R., Bauman, J., Kang, H., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 304
Vascular permeability—the essentials
Claesson-Welsh, L. (2015) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2015.1064501 · Cited by 304
“VEGF-blocking antibodies or VEGFR kinase inhibitors therefore induces a more normal tumor vessel morphology and attenuates the exaggerated permeability (56).”
BackgroundImmunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“Repairing the structure and function of the vascular network can improve tumour perfusion and oxygenation 223 , thereby enhancing drug delivery and decreasing tumour hypoxia, which in turn can decrease tumour malignancy, set an immunostimulatory microenvironment 223,224 and improve the therapeutic…”
Exercise-dependent regulation of the tumour microenvironment
Koelwyn, G. J., Quail, D. F., Zhang, X., White, R. M., & Jones, L. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.78 · Cited by 296
Song, X., Xu, J., Liang, C., Chao, Y., Jin, Q., Wang, C., Chen, M., & Liu, Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02720 · Cited by 298
Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3
Saunders, W. B., Bohnsack, B. L., Faske, J. B., Anthis, N. J., Bayless, K. J., Hirschi, K. K., & Davis, G. E. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200603176 · Cited by 296
“The inhibition of VEGFR-2 is a major therapeutic target in antiangiogenic protocols to inhibit excess vascularization in tumors and other contexts (Jain, 2005).”
BackgroundThe renin-angiotensin system and malignancy
Ager, E. I., Neo, J., & Christophi, C. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn171 · Cited by 295
Vascular Endothelial Growth Factor and Its Relationship to Inflammatory Mediators
Angelo, L. S., & Kurzrock, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2416 · Cited by 295
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
“Finally, the vessel normalization rather than the disruption of tumor vasculature has been implied to provide antiangiogenic therapy benefits ( 41 ).”
Background(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
“Blockade of VEGF results in extensive pruning of the rapidly growing tumour vasculature, decreasing tumour vessel density and normalizing the remaining vessel”
BackgroundCombining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
“This dose- and time-dependency of vascular normalization results in a “normalization window” within which perfusion is improved (33, 38).”
InfluentialSelf-citationRuan, S., Cao, X., Cun, X., Hu, G., Zhou, Y., Zhang, Y., Lu, L., He, Q., & Gao, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.05.006 · Cited by 290
[6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo
Kim, E.-C., Min, J.-K., Kim, T.-Y., Lee, S.-J., Yang, H.-O., Han, S., Kim, Y.-M., & Kwon, Y.-G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.076 · Cited by 290
Epithelial-mesenchymal transition in glioblastoma progression
IWADATE, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4113 · Cited by 288
“…important factors facilitating angiogenesis and resultant tumor growth in GBM. Inhibiting the VEGF-VEGF receptor (VEGFR) signal transduction pathway with anti-VEGF therapy (including the use of bevacizumab) and VEGFR inhibitors (including sunitinib) is a promising strategy in cancer therapy (80).”
Glioma: experimental models and reality
Lenting, K., Verhaak, R., ter Laan, M., Wesseling, P., & Leenders, W. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 287
“Meanwhile, reduction of hyperpermeability of brain tumor microvessels by anti-VEGF-A treatment may have a rapid positive effect on edematous brain swelling, thereby temporarily improving the quality of life [37, 70].”
Burkly, L. C., Michaelson, J. S., Hahm, K., Jakubowski, A., & Zheng, T. S. (2007) · Cytokine · doi:10.1016/j.cyto.2007.09.007 · Cited by 286
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Castells, M., Thibault, B., Delord, J.-P., & Couderc, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13089545 · Cited by 285
“Not only does this allow a better delivery of chemotherapy and increase the sensitivity to radiotherapy but it also decreases tumor cell extravasation and migration in the blood circulation by reestablishing the endothelial cell barrier [55,59].”
BackgroundTargeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
“pericytes and perivascular cells, and an increased permeability, resulting in a leaky vascular system (9).”
BackgroundNeutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy
Binet, F., Cagnone, G., Crespo-Garcia, S., Hata, M., Neault, M., Dejda, A., Wilson, A. M., Buscarlet, M., Mawambo, G. T., Howard, J. P., et al. (2020) · Science · doi:10.1126/science.aay5356 · Cited by 283
Bosch, A., Eroles, P., Zaragoza, R., Viña, J. R., & Lluch, A. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.002 · Cited by 283
Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole
Lee, S. T., & Scott, A. M. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.07.001 · Cited by 283
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
Impact of Metabolic Heterogeneity on Tumor Growth, Invasion, and Treatment Outcomes
Robertson-Tessi, M., Gillies, R. J., Gatenby, R. A., & Anderson, A. R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1428 · Cited by 279
“Cancer Res; 75(8) April 15, 2015 Cancer Research 1572”
BackgroundInfluentialYasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Current Applications of Nanoemulsions in Cancer Therapeutics
Sánchez-López, E., Guerra, M., Dias-Ferreira, J., Lopez-Machado, A., Ettcheto, M., Cano, A., Espina, M., Camins, A., Garcia, M. L., & Souto, E. B. (2019) · Nanomaterials · doi:10.3390/nano9060821 · Cited by 276
“Active targeting moieties connect to over-expressed receptors in cancer cells like folate [18], transferrin [19], epidermal growth factor (EFGR) [20], or prostate-specific membrane antigen (PSMA) [21].”
BackgroundRepurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Verbaanderd, C., Maes, H., Schaaf, M. B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.781 · Cited by 275
Unraveling the Role of Angiogenesis in Cancer Ecosystems
Zuazo-Gaztelu, I., & Casanovas, O. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00248 · Cited by 275
Lauwers, F., Cassot, F., Lauwers-Cances, V., Puwanarajah, P., & Duvernoy, H. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.024 · Cited by 274
“In the area of tumour angiogenesis, characterizing a normal or normalized vascular network is an unavoidable step in identifying any pathological change or therapeutic anti-angiogenic effect (Jain, 2005).”
BackgroundAli, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C., Rutka, J. T., & Zadeh, G. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 272
Fibronectins in vascular morphogenesis
Astrof, S., & Hynes, R. O. (2009) · Angiogenesis · doi:10.1007/s10456-009-9136-6 · Cited by 271
“extracellular matrix, which includes FN and its splice variants, surrounds tumor vessels [103, 109].”
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00602-3 · Cited by 267
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.